Muroyama, Ryosuke

Publishing since 2005 (Junior)

Has published 11 publications in 5 years

Number of publications published per year by Muroyama, Ryosuke. (Source : PubMed)

Distribution of publications types for Muroyama, Ryosuke. (Source : PubMed)
(a publication can be of different types, so total may exceed publications count)

Recent publications

•  Hu Z, Muroyama R, Kowatari N, Chang J, Omata M, Kato N. Characteristic mutations in hepatitis C virus core gene related to the occurrence of hepatocellular carcinoma.  Cancer Sci.  2009;100;12  
•  Chang JH, Kato N, Muroyama R, Taniguchi H, Guleng B, Dharel N, Shao RX, Tateishi K, Jazag A, Kawabe T, Omata M. Double-stranded RNA-activated protein kinase inhibits hepatitis C virus replication but may be not essential in interferon treatment.  Liver Int.  2009  
•  Li CZ, Kato N, Chang JH, Muroyama R, Shao RX, Dharel N, Sermsathanasawadi R, Kawabe T, Omata M. Polymorphism of OAS-1 determines liver fibrosis progression in hepatitis C by reduced ability to inhibit viral replication.  Liver Int.  2009;29;9  
•  Sermasathanasawadi R, Kato N, Muroyama R, Dharel N, Shao RX, Chang JH, Li CZ, Kawabe T, Omata M. Association of interferon regulatory factor-7 gene polymorphism with liver cirrhosis in chronic hepatitis C patients.  Liver Int.  2008;28;6  
•  Tada M, Kanai F, Tanaka Y, Tateishi K, Ohta M, Asaoka Y, Seto M, Muroyama R, Fukai K, Imazeki F, Kawabe T, Yokosuka O, Omata M. Down-regulation of hedgehog-interacting protein through genetic and epigenetic alterations in human hepatocellular carcinoma.  Clin. Cancer Res.  2008;14;12  
•  Dharel N, Kato N, Muroyama R, Taniguchi H, Otsuka M, Wang Y, Jazag A, Shao RX, Chang JH, Adler MK, Kawabe T, Omata M. Potential contribution of tumor suppressor p53 in the host defense against hepatitis C virus.  Hepatology  2008;47;4  
•  Shao RX, Kato N, Lin LJ, Muroyama R, Moriyama M, Ikenoue T, Watabe H, Otsuka M, Guleng B, Ohta M, Tanaka Y, Kondo S, Dharel N, Chang JH, Yoshida H, Kawabe T, Omata M. Absence of tyrosine kinase mutations in Japanese colorectal cancer patients.  Oncogene  2007;26;14  
•  Muroyama R, Kato N, Yoshida H, Otsuka M, Moriyama M, Wang Y, Shao RX, Dharel N, Tanaka Y, Ohta M, Tateishi R, Shiina S, Tatsukawa M, Fukai K, Imazeki F, Yokosuka O, Shiratori Y, Omata M. Nucleotide change of codon 38 in the X gene of hepatitis B virus genotype C is associated with an increased risk of hepatocellular carcinoma.  J. Hepatol.  2006;45;6  
•  Dharel N, Kato N, Muroyama R, Moriyama M, Shao RX, Kawabe T, Omata M. MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C.  Clin. Cancer Res.  2006;12;16  
•  Shao RX, Otsuka M, Kato N, Chang JH, Muroyama R, Taniguchi H, Moriyama M, Wang Y, Kawabe T, Omata M. No mutations in the tyrosine kinases of human hepatic, pancreatic, and gastric cancer cell lines.  J. Gastroenterol.  2005;40;9  

[ See timeline ] [ See all publications ]